CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 483 enrolled
Drug / intervention
Erenumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01952574
NCT01952574Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention

Amgen·interventional·Posted Sep 30, 2013·Updated Oct 12, 2022

In Brief

A Phase 2 clinical trial evaluating Erenumab, Placebo, and 2 other interventions for Migraine. Completed, enrolled 483 participants across 66 sites in 7 countries.

Detailed Summary

A study to evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days in participants with episodic migraine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesCanada, Denmark, Finland, Germany, Norway, Sweden, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 30, 2013
Enrollment StartAug 6, 2013
Primary CompletionSep 25, 2014
Study CompletionNov 12, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 12.8 years ago

Interventions

Erenumabdrug

Administered by study site staff once a month (QM) as a subcutaneous injection

Placebodrug

Administered by study site staff once a month (QM) as a subcutaneous injection

Erenumab PFSdrug

Erenumab supplied in a single-use prefilled syringe for self-administration in the CHU substudy

Erenumab AI/Pendrug

Erenumab supplied in a single-use autoinjector/pen for self-administration in the CHU substudy